Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Goodwill: 2019-2024

Historic Goodwill for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $9.4 million.

  • Silence Therapeutics' Goodwill rose 12.99% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year increase of 12.99%. This contributed to the annual value of $9.4 million for FY2024, which is 5.90% down from last year.
  • Latest data reveals that Silence Therapeutics reported Goodwill of $9.4 million as of FY2024, which was down 5.90% from $10.0 million recorded in FY2023.
  • Silence Therapeutics' Goodwill's 5-year high stood at $10.4 million during FY2021, with a 5-year trough of $9.4 million in FY2024.
  • Moreover, its 3-year median value for Goodwill was $9.7 million (2022), whereas its average is $9.7 million.
  • As far as peak fluctuations go, Silence Therapeutics' Goodwill rose by 6.23% in 2020, and later decreased by 7.30% in 2022.
  • Over the past 5 years, Silence Therapeutics' Goodwill (MRY) stood at $10.4 million in 2020, then increased by 0.11% to $10.4 million in 2021, then fell by 7.30% to $9.7 million in 2022, then grew by 3.08% to $10.0 million in 2023, then decreased by 5.90% to $9.4 million in 2024.
  • Its Goodwill stands at $9.4 million for FY2024, versus $10.0 million for FY2023 and $9.7 million for FY2022.